Imjudo savings card: as little as $0 an infusion with commercial insurance

Imjudo is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How to pay the least

Given by your care team

Billed by the clinic

Imjudo is given by a doctor or nurse, not picked up at a pharmacy.

Ask your care team or your plan what you’d pay before your visit.

Compare every option

Brand nameImjudo

Authorized generictremelimumab

Regular generictremelimumab

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldAsk the pharmacy

Same as Imjudo?

The original

–

Brand nameThe maker’s card

IMJUDO Co-pay Savings Program (AstraZeneca Access 360)

Savings card from AstraZeneca

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $0 an infusion

Or call 1-844-275-2360.

In the maker’s words

“Eligible patients may pay as little as $0 per infusion for IMFINZI and/or IMJUDO.”

From the maker’s offer on myaccess360.com, checked October 27, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Imjudo itself, from the same company, sold without the brand name, and usually for less. For now Imjudo is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Imjudo is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

IMJUDO is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated:

in combination with durvalumab, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC).
in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.

Source: the FDA label for Imjudo (AstraZeneca Pharmaceuticals LP), August 31, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to the clinic’s billing office.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked October 27, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/imjudo/